Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Trial Profile

An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INBRX 109 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Mesothelioma; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Inhibrx
  • Most Recent Events

    • 03 Sep 2019 According to a Inhibrx media release, the efficacy and safety data from the dose expansion cohorts is expected to be reported in the second quarter of 2020.
    • 03 Sep 2019 According to a Inhibrx media release, the company announced the completion of the dose escalation portion of this study. The dose expansion portion of the trial will now begin enrollment, with planned 20 patient cohorts in each of gastric and colorectal adenocarcinomas as well as mesothelioma.
    • 03 Sep 2019 Results (n=20) of the phase escalation portion of this study published in the Inhibrx Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top